Hanne Christensen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Recognitions
Hanne Christensen has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:
- Inger Havsteen
Department of Radiology, Bispebjerg Hospital, Copenhagen, Denmark
25 shared publications Bo Norrving
Department of Clinical Sciences, Lund University , Lund
18 shared publications- Philip Mw Bath
Stroke, Division of Clinical Neuroscience, University of Nottingham, Nottingham, UK
18 shared publications - Daniel Kim
Department of Public Health and Health Sciences, School of Community Health and Behavioral Sciences, Northeastern University, Boston, Massachusetts, USA
16 shared publications - Graeme J. Hankey
Centre for Neuromuscular and Neurological Disorders, Medical School, The University of Western Australia, Perth, WA, Australia
16 shared publications - Kingsley Nnanna Ukwaja
Department of Medicine, College of Medical Sciences, Alex Ekwueme Federal University, Ndufu-Alike Ikwo 480214, Ebonyi State, Nigeria
16 shared publications
Latest Publications
- 13 November 2026
- Published by Wolters Kluwer Health in Stroke
Predictors of Thrombotic Events and Mortality in Patients Treated With Andexanet: A Pooled Analysis
BACKGROUND: Andexanet reduces hematoma expansion compared with usual care for acute FXa (factor Xa) inhibitor-associated intracerebral hemorrhage but is associated with a risk of thrombotic events (TE). We pooled data from andexanet-treated trial participants to determine baseline predictors of TE. METHODS: Secondary analyses of andexanet-treated participants in ANNEXA-I (Andexanet Alfa, a Novel Antidote to the Anticoagulant Effects of Factor Xa Inhibitors in ICH) and ANNEXA-4 (Andexanet Alfa, a Novel Antidote to the Anticoagulation Effects of Factor Xa Inhibitors), which included adults with acute life-threatening hemorrhage on FXa inhibitors. Stratified Cox proportional hazards models were used to examine associations between baseline variables and arterial or all TE and mortality. A stratified Cox regression model with arterial events as time-dependent covariates was used to examine associations of arterial events with mortality, adjusted for clinical covariates. RESULTS: Of 741 participants (mean age, 78.5 years; 54.5% male), 593 (80.0%) had intracranial hemorrhage and 109 (14.7%) had gastrointestinal hemorrhage. Seventy-seven (10.4%) participants had ≥1 TE, and 147 (19.8%) died. Arterial and venous thromboembolism events occurred a median of 3.5 days (interquartile range, 2.0–12.0) and 14.0 days (interquartile range, 10.0–20.0), respectively, after randomization. No baseline factors were associated with all TE. Arterial TE were associated with prior myocardial infarction (hazard ratio [HR], 2.64 [95% CI, 1.33–5.26]), high-dose eligibility (HR, 2.44 [95% CI, 1.33–4.48]), female sex (HR, 1.78 [95% CI, 1.00–3.16]), and age (HR per year, 1.04 [95% CI, 1.00–1.08]). Mortality was associated with arterial TE (HR, 2.68 [95% CI, 1.64–4.36]), prior congestive heart failure (HR, 2.53 [95% CI, 1.76–3.63]), intracerebral hemorrhage or intraventricular hemorrhage (HR, 1.90 [95% CI, 1.20–3.01]), and age (HR per year, 1.06 [95% CI, 1.03–1.08]). The initiation of anticoagulation after randomization was associated with a reduction in TE. CONCLUSIONS: In FXa inhibitor-associated hemorrhage treated with andexanet, baseline factors are associated with arterial TE and can be used to inform treatment decisions. Initiation of anticoagulation reduces the occurrence of TE. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02313909. URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02329327.
- 13 November 2026
- Published by Wolters Kluwer Health in Stroke
Predictors of Thrombotic Events and Mortality in Patients Treated With Andexanet: A Pooled Analysis
BACKGROUND: Andexanet reduces hematoma expansion compared with usual care for acute FXa (factor Xa) inhibitor-associated intracerebral hemorrhage but is associated with a risk of thrombotic events (TE). We pooled data from andexanet-treated trial participants to determine baseline predictors of TE. METHODS: Secondary analyses of andexanet-treated participants in ANNEXA-I (Andexanet Alfa, a Novel Antidote to the Anticoagulant Effects of Factor Xa Inhibitors in ICH) and ANNEXA-4 (Andexanet Alfa, a Novel Antidote to the Anticoagulation Effects of Factor Xa Inhibitors), which included adults with acute life-threatening hemorrhage on FXa inhibitors. Stratified Cox proportional hazards models were used to examine associations between baseline variables and arterial or all TE and mortality. A stratified Cox regression model with arterial events as time-dependent covariates was used to examine associations of arterial events with mortality, adjusted for clinical covariates. RESULTS: Of 741 participants (mean age, 78.5 years; 54.5% male), 593 (80.0%) had intracranial hemorrhage and 109 (14.7%) had gastrointestinal hemorrhage. Seventy-seven (10.4%) participants had ≥1 TE, and 147 (19.8%) died. Arterial and venous thromboembolism events occurred a median of 3.5 days (interquartile range, 2.0–12.0) and 14.0 days (interquartile range, 10.0–20.0), respectively, after randomization. No baseline factors were associated with all TE. Arterial TE were associated with prior myocardial infarction (hazard ratio [HR], 2.64 [95% CI, 1.33–5.26]), high-dose eligibility (HR, 2.44 [95% CI, 1.33–4.48]), female sex (HR, 1.78 [95% CI, 1.00–3.16]), and age (HR per year, 1.04 [95% CI, 1.00–1.08]). Mortality was associated with arterial TE (HR, 2.68 [95% CI, 1.64–4.36]), prior congestive heart failure (HR, 2.53 [95% CI, 1.76–3.63]), intracerebral hemorrhage or intraventricular hemorrhage (HR, 1.90 [95% CI, 1.20–3.01]), and age (HR per year, 1.06 [95% CI, 1.03–1.08]). The initiation of anticoagulation after randomization was associated with a reduction in TE. CONCLUSIONS: In FXa inhibitor-associated hemorrhage treated with andexanet, baseline factors are associated with arterial TE and can be used to inform treatment decisions. Initiation of anticoagulation reduces the occurrence of TE. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02313909. URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02329327.
- 13 October 2026
- Published by Wolters Kluwer Health in Circulation
Bleeding With Asundexian Versus Placebo in Patients With Noncardioembolic Ischemic Stroke or High-Risk TIA: OCEANIC-STROKE Randomized Trial
BACKGROUND: OCEANIC-STROKE (XXX) showed that asundexian added to antiplatelet therapy reduced ischemic stroke without significantly increasing bleeding in patients with noncardioembolic ischemic stroke or high-risk transient ischemic attack. We characterized bleeding categories, sites, and key subgroups. METHODS: In the safety population, 12 254 participants received at least 1 dose of asundexian (n=6124) or placebo (n=6130). Bleeding was categorized by International Society on Thrombosis and Haemostasis criteria as major, clinically relevant nonmajor (CRNM), or minor. While-on-treatment analyses included events through 2 days after the last dose, with death and permanent discontinuation as competing risks. RESULTS: Major bleeding occurred in 117 (1.9%) participants with asundexian and 107 (1.7%) with placebo (cause-specific hazard ratio [csHR], 1.10 [95% CI, 0.85–1.44]; P =0.46). Major or CRNM bleeding occurred in 339 (5.5%) and 307 (5.0%), respectively (csHR, 1.12 [95% CI, 0.96–1.30]; P =0.16), and any bleeding in 763 (12.5%) and 752 (12.3%) (csHR, 1.02 [95% CI, 0.93–1.13]; P =0.65). Treatment effects for major and major or CRNM bleeding were consistent across prespecified subgroups, including planned dual antiplatelet therapy. Symptomatic intracranial hemorrhage occurred in 41 (0.7%) and 36 (0.6%) participants. Any gastrointestinal bleeding occurred in 186 (3.0%) and 147 (2.4%) (csHR, 1.28 [95% CI, 1.03–1.59]), and lower gastrointestinal bleeding in 102 (1.7%) and 59 (1.0%) (csHR, 1.75 [95% CI, 1.27–2.41]), primarily rectal bleeding. Any procedure-related bleeding and any mucosal bleeding did not differ significantly. CONCLUSIONS: Asundexian added to antiplatelet therapy reduced ischemic stroke without significantly increasing major, major or CRNM, or any bleeding. Lower gastrointestinal bleeding was more frequent with asundexian, whereas treatment effects on major and major or CRNM bleeding were consistent across prespecified subgroups. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique Identifier: NCT05686070.
- 13 October 2026
- Published by Wolters Kluwer Health in Circulation
Bleeding With Asundexian Versus Placebo in Patients With Noncardioembolic Ischemic Stroke or High-Risk TIA: OCEANIC-STROKE Randomized Trial
BACKGROUND: OCEANIC-STROKE (XXX) showed that asundexian added to antiplatelet therapy reduced ischemic stroke without significantly increasing bleeding in patients with noncardioembolic ischemic stroke or high-risk transient ischemic attack. We characterized bleeding categories, sites, and key subgroups. METHODS: In the safety population, 12 254 participants received at least 1 dose of asundexian (n=6124) or placebo (n=6130). Bleeding was categorized by International Society on Thrombosis and Haemostasis criteria as major, clinically relevant nonmajor (CRNM), or minor. While-on-treatment analyses included events through 2 days after the last dose, with death and permanent discontinuation as competing risks. RESULTS: Major bleeding occurred in 117 (1.9%) participants with asundexian and 107 (1.7%) with placebo (cause-specific hazard ratio [csHR], 1.10 [95% CI, 0.85–1.44]; P =0.46). Major or CRNM bleeding occurred in 339 (5.5%) and 307 (5.0%), respectively (csHR, 1.12 [95% CI, 0.96–1.30]; P =0.16), and any bleeding in 763 (12.5%) and 752 (12.3%) (csHR, 1.02 [95% CI, 0.93–1.13]; P =0.65). Treatment effects for major and major or CRNM bleeding were consistent across prespecified subgroups, including planned dual antiplatelet therapy. Symptomatic intracranial hemorrhage occurred in 41 (0.7%) and 36 (0.6%) participants. Any gastrointestinal bleeding occurred in 186 (3.0%) and 147 (2.4%) (csHR, 1.28 [95% CI, 1.03–1.59]), and lower gastrointestinal bleeding in 102 (1.7%) and 59 (1.0%) (csHR, 1.75 [95% CI, 1.27–2.41]), primarily rectal bleeding. Any procedure-related bleeding and any mucosal bleeding did not differ significantly. CONCLUSIONS: Asundexian added to antiplatelet therapy reduced ischemic stroke without significantly increasing major, major or CRNM, or any bleeding. Lower gastrointestinal bleeding was more frequent with asundexian, whereas treatment effects on major and major or CRNM bleeding were consistent across prespecified subgroups. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique Identifier: NCT05686070.
- Open Access
- 5 September 2026
- Published by Oxford University Press (OUP) in European Stroke Journal
- Vol. 11 (9)
Response to “Perhaps Fewer, but Faster: Should we Rethink the 90% Stroke Unit Admission Standard?”
- 5 September 2026
- Published by Oxford University Press (OUP) in European Stroke Journal
- Vol. 11 (9)
Open AccessResponse to “Perhaps Fewer, but Faster: Should we Rethink the 90% Stroke Unit Admission Standard?”
- Open Access
- 5 September 2026
- Published by Oxford University Press (OUP) in European Stroke Journal
- Vol. 11 (9)
Response to Middleton et al.
- 5 September 2026
- Published by Oxford University Press (OUP) in European Stroke Journal
- Vol. 11 (9)
Open AccessResponse to Middleton et al.
- Open Access
- 6 July 2026
- Published by Oxford University Press (OUP) in European Stroke Journal
- Vol. 11 (7)
Accessibility and use of organised stroke care and reperfusion therapies in Europe: results from the SAP-E Stroke Service Tracker 2023
Introduction: Organised stroke care and reperfusion therapies are key components of modern stroke treatment. We assessed accessibility of organised stroke care and reperfusion therapies in Europe and explored its association with key organisational indicators. Patients and methods: Stroke Action Plan for Europe (SAP-E) Stroke Service Tracker data from 2023 reported by 47 European countries was assessed. Accessibility indicators included stroke unit (SU) admission proportions, intravenous thrombolysis (IVT) and EVT treatment proportions. Organisational indicators included the facility density of SU, IVT-capable centres and EVT-capable centres per capita (number of centres per 100,000 population), presence of national stroke plans and quality programmes. Results: Across Europe, marked variations were observed in facility density of SU (0.21–0.48), IVT-capable centres (0.19–0.45) and EVT-capable centres (0.06–0.15). SU admission proportions ranked from 0.8% to 96.7%, IVT treatment proportions from 1.3% to 34.7% and EVT treatment proportions from 0.2% to 14.3%. Stroke unit admission proportions were associated with SU density (r = 0.42, P = .03). Density of reperfusion-capable centres showed a possible trending association with IVT treatment proportions (r = 0.34, P = .08), but no association with EVT treatment proportions (r = 0.22, P = .23). Neither the presence of a national stroke plan nor a quality programme were associated with accessibility of SU care, IVT or EVT. Conclusion: Large inequities in access to organised stroke care and reperfusion therapies persist across Europe. At the country level, national stroke plans and quality programmes have not yet translated into effect on accessibility indicators, suggesting that achieving effective implementation takes time or could primarily manifest as within-country improvements.
- 6 July 2026
- Published by Oxford University Press (OUP) in European Stroke Journal
- Vol. 11 (7)
Open AccessAccessibility and use of organised stroke care and reperfusion therapies in Europe: results from the SAP-E Stroke Service Tracker 2023
Introduction: Organised stroke care and reperfusion therapies are key components of modern stroke treatment. We assessed accessibility of organised stroke care and reperfusion therapies in Europe and explored its association with key organisational indicators. Patients and methods: Stroke Action Plan for Europe (SAP-E) Stroke Service Tracker data from 2023 reported by 47 European countries was assessed. Accessibility indicators included stroke unit (SU) admission proportions, intravenous thrombolysis (IVT) and EVT treatment proportions. Organisational indicators included the facility density of SU, IVT-capable centres and EVT-capable centres per capita (number of centres per 100,000 population), presence of national stroke plans and quality programmes. Results: Across Europe, marked variations were observed in facility density of SU (0.21–0.48), IVT-capable centres (0.19–0.45) and EVT-capable centres (0.06–0.15). SU admission proportions ranked from 0.8% to 96.7%, IVT treatment proportions from 1.3% to 34.7% and EVT treatment proportions from 0.2% to 14.3%. Stroke unit admission proportions were associated with SU density (r = 0.42, P = .03). Density of reperfusion-capable centres showed a possible trending association with IVT treatment proportions (r = 0.34, P = .08), but no association with EVT treatment proportions (r = 0.22, P = .23). Neither the presence of a national stroke plan nor a quality programme were associated with accessibility of SU care, IVT or EVT. Conclusion: Large inequities in access to organised stroke care and reperfusion therapies persist across Europe. At the country level, national stroke plans and quality programmes have not yet translated into effect on accessibility indicators, suggesting that achieving effective implementation takes time or could primarily manifest as within-country improvements.
- 6 July 2026
- Published by Springer Nature in GeroScience
Pharmacological management of transient focal neurological episodes in cerebral amyloid angiopathy: a systematic review
Cerebral amyloid angiopathy (CAA) is associated with transient focal neurological episodes (TFNEs), which are brief, stereotyped symptoms. As these may occur regularly, pharmacological treatment of TFNEs is needed but remains poorly investigated. To systematically evaluate the available evidence on the use of pharmacological treatment to reduce the frequency, severity, or duration of TFNEs in patients with CAA. A systematic literature search of PubMed and Embase was conducted. Eligible studies included observational studies, interventional trials, and case reports or series that assessed pharmacological interventions for TFNEs in patients with confirmed CAA. Nine case reports/series involving 13 patients met the inclusion criteria. The mean age was 75.15 years, with a predominance of sensory and motor TFNE symptoms. One EEG recording out of nine reported paroxysmal activity whereas the rest showed no epileptiform activity. Antiseizure medications (levetiracetam) were the most common treatment. Eleven patients experienced complete remission, and two had partial improvement. Most patients exhibited convexity subarachnoid hemorrhage or cortical superficial siderosis on imaging. Although symptomatic improvement following pharmacological treatment was commonly reported, the current evidence is limited to descriptive case reports without control groups. The unpredictable course of TFNEs and absence of long-term follow-up complicate treatment evaluation. Larger, controlled studies or observational studies are needed to establish effective and evidence-based treatment strategies for TFNEs in CAA.
- 6 July 2026
- Published by Springer Nature in GeroScience
Pharmacological management of transient focal neurological episodes in cerebral amyloid angiopathy: a systematic review
Cerebral amyloid angiopathy (CAA) is associated with transient focal neurological episodes (TFNEs), which are brief, stereotyped symptoms. As these may occur regularly, pharmacological treatment of TFNEs is needed but remains poorly investigated. To systematically evaluate the available evidence on the use of pharmacological treatment to reduce the frequency, severity, or duration of TFNEs in patients with CAA. A systematic literature search of PubMed and Embase was conducted. Eligible studies included observational studies, interventional trials, and case reports or series that assessed pharmacological interventions for TFNEs in patients with confirmed CAA. Nine case reports/series involving 13 patients met the inclusion criteria. The mean age was 75.15 years, with a predominance of sensory and motor TFNE symptoms. One EEG recording out of nine reported paroxysmal activity whereas the rest showed no epileptiform activity. Antiseizure medications (levetiracetam) were the most common treatment. Eleven patients experienced complete remission, and two had partial improvement. Most patients exhibited convexity subarachnoid hemorrhage or cortical superficial siderosis on imaging. Although symptomatic improvement following pharmacological treatment was commonly reported, the current evidence is limited to descriptive case reports without control groups. The unpredictable course of TFNEs and absence of long-term follow-up complicate treatment evaluation. Larger, controlled studies or observational studies are needed to establish effective and evidence-based treatment strategies for TFNEs in CAA.
- Open Access
- 1 July 2026
- Published by Oxford University Press (OUP) in Brain Communications
- Vol. 8 (4)
Neurovascular effects of tadalafil in patients with cerebral small vessel disease: ETLAS-2 substudy
Cerebral small vessel disease is a major contributor to stroke and cognitive impairment, often associated with reduced cerebral blood flow and cerebrovascular reactivity. In this study, we used MRI to investigate if daily treatment with the phosphodiesterase-5 inhibitor tadalafil over 3 months improved cerebral blood flow and cerebrovascular reactivity in patients with cerebral small vessel disease. Using a randomized, placebo-controlled, parallel-group design, this MRI sub-study was prospectively performed as part of the Effect of Tadalafil in Lacunar Stroke 2 trial, which included a total of 76 participants, of whom 60 were included in the per-protocol analysis. Patients with cerebral small vessel disease and prior stroke or transient ischaemic attack received either tadalafil (20 mg/day) or placebo for 3 months and completed the study. Neurovascular outcomes were assessed at baseline and at the 3-month follow-up using dual-echo pseudo-continuous arterial spin labelling MRI to evaluate reactivity to hypercapnia and visual stimulation. Endpoints included changes in whole-brain baseline cerebral blood flow and cerebrovascular reactivity, visual stimulation response, and neurovascular coupling index. In addition, we investigated arterial transit time measured using diffusion-prepared pseudo-continuous arterial spin labelling and changes in event-related sensory blood-oxygen-level-dependent responses in the primary somatosensory cortex (S1) after stimulation of the index finger. In total, 60 participants (median age: 66.5, 14 females) were included in this per-protocol sub-study analysis (28 on tadalafil and 32 on placebo). Forty-two pseudo-continuous arterial spin labelling datasets (20 on tadalafil and 22 on placebo), 53 blood-oxygen-level-dependent functional MRI datasets (26 on tadalafil and 27 on placebo), and 45 arterial transit time datasets (22 on tadalafil and 23 on placebo) were of sufficient quality to be included in the analysis. Baseline whole-brain cerebral blood flow was 25.4 ± 5.1 ml/100 g/min. Compared to placebo, tadalafil significantly increased whole-brain cerebral blood flow with a mean group difference of 3.33 ± 0.97 ml/100 g/min at follow-up (P = 0.001). None of the other MRI-based outcome metrics differed between groups. Three months of tadalafil treatment significantly enhanced whole-brain cerebral blood flow in patients with cerebral small vessel disease without altering cerebrovascular reactivity, neurovascular coupling, arterial transit time, and event-related blood-oxygen-level-dependent responses. The clinical significance of a tadalafil-induced increase in cerebral blood flow remains to be determined in prospective studies covering longer treatment periods.
- 1 July 2026
- Published by Oxford University Press (OUP) in Brain Communications
- Vol. 8 (4)
Open AccessNeurovascular effects of tadalafil in patients with cerebral small vessel disease: ETLAS-2 substudy
Cerebral small vessel disease is a major contributor to stroke and cognitive impairment, often associated with reduced cerebral blood flow and cerebrovascular reactivity. In this study, we used MRI to investigate if daily treatment with the phosphodiesterase-5 inhibitor tadalafil over 3 months improved cerebral blood flow and cerebrovascular reactivity in patients with cerebral small vessel disease. Using a randomized, placebo-controlled, parallel-group design, this MRI sub-study was prospectively performed as part of the Effect of Tadalafil in Lacunar Stroke 2 trial, which included a total of 76 participants, of whom 60 were included in the per-protocol analysis. Patients with cerebral small vessel disease and prior stroke or transient ischaemic attack received either tadalafil (20 mg/day) or placebo for 3 months and completed the study. Neurovascular outcomes were assessed at baseline and at the 3-month follow-up using dual-echo pseudo-continuous arterial spin labelling MRI to evaluate reactivity to hypercapnia and visual stimulation. Endpoints included changes in whole-brain baseline cerebral blood flow and cerebrovascular reactivity, visual stimulation response, and neurovascular coupling index. In addition, we investigated arterial transit time measured using diffusion-prepared pseudo-continuous arterial spin labelling and changes in event-related sensory blood-oxygen-level-dependent responses in the primary somatosensory cortex (S1) after stimulation of the index finger. In total, 60 participants (median age: 66.5, 14 females) were included in this per-protocol sub-study analysis (28 on tadalafil and 32 on placebo). Forty-two pseudo-continuous arterial spin labelling datasets (20 on tadalafil and 22 on placebo), 53 blood-oxygen-level-dependent functional MRI datasets (26 on tadalafil and 27 on placebo), and 45 arterial transit time datasets (22 on tadalafil and 23 on placebo) were of sufficient quality to be included in the analysis. Baseline whole-brain cerebral blood flow was 25.4 ± 5.1 ml/100 g/min. Compared to placebo, tadalafil significantly increased whole-brain cerebral blood flow with a mean group difference of 3.33 ± 0.97 ml/100 g/min at follow-up (P = 0.001). None of the other MRI-based outcome metrics differed between groups. Three months of tadalafil treatment significantly enhanced whole-brain cerebral blood flow in patients with cerebral small vessel disease without altering cerebrovascular reactivity, neurovascular coupling, arterial transit time, and event-related blood-oxygen-level-dependent responses. The clinical significance of a tadalafil-induced increase in cerebral blood flow remains to be determined in prospective studies covering longer treatment periods.
- Open Access
- 1 July 2026
- Published by Wolters Kluwer Health in Stroke
- Vol. 57 (7) , 1920-1928
Predictors of Hematoma Expansion and Response to Andexanet in Patients With Intracerebral Hemorrhage: Secondary Analyses of the ANNEXA-I Randomized Clinical Trial
BACKGROUND: Andexanet improves hemostatic efficacy in FXa (factor Xa) inhibitor–associated intracranial hemorrhage but carries a risk of thrombotic events. These secondary analyses of the ANNEXA-I trial (A Randomized Clinical Trial of Andexanet Alfa in Acute Intracranial Hemorrhage in Patients Receiving an Oral Factor Xa Inhibitor) examined determinants of hematoma expansion (HE) and the corresponding response to andexanet. METHODS: ANNEXA-I enrolled patients aged ≥18 years with acute FXa inhibitor–associated intracranial hemorrhage within 6 hours of onset between June 6, 2019, and May 27, 2023, at 131 sites in 23 countries. Participants were randomized (1:1) to andexanet or usual care. Among 530 participants, 459 (87%) had a qualifying intracerebral hemorrhage and adequate brain imaging for these analyses. The primary outcome was HE (≥12.5-mL or ≥35% increase in baseline volume) at 12 hours. We report differences in the proportion of HE between treatment groups stratified by variables significantly associated with HE in regression models. RESULTS: HE occurred in 149 of 459 participants (32.5%). Symptom onset-to-treatment time (adjusted odds ratio per hour, 0.73 [95% CI, 0.63–0.85]), baseline hematoma volume (adjusted odds ratio per 10 mL, 1.11 [95% CI, 1.01–1.23]), and diastolic blood pressure (adjusted odds ratio per 10 mm Hg, 1.15 [95% CI, 1.02–1.29]) were associated with HE but not thrombotic events. In a separate multivariable model replacing volume and onset-to-treatment time with prescan hematoma growth rate, growth rate was also associated with HE (adjusted odds ratio per mL/h, 1.02 [95% CI, 1.01–1.04]). Patients in the highest risk quartiles (baseline volume >22.4 mL, growth rate >11.4 mL/h, diastolic blood pressure >95.0 mm Hg, and onset-to-treatment time ≤3.3 hours) had ≈50% to 60% absolute risk of HE with usual care. Numerically greater absolute risk reductions with andexanet (≈25%; number needed to treat: 4) were observed in the highest quartiles of baseline volume and growth rate. CONCLUSIONS: Shorter onset-to-treatment time, larger baseline hematoma volume, higher diastolic blood pressure, and higher prescan hematoma growth rate predict HE but not thrombotic events in FXa inhibitor–associated intracerebral hemorrhage. Andexanet benefit is observed across these ranges and may be amplified through patient selection using these metrics. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03661528.
- 1 July 2026
- Published by Wolters Kluwer Health in Stroke
- Vol. 57 (7) , 1920-1928
Open AccessPredictors of Hematoma Expansion and Response to Andexanet in Patients With Intracerebral Hemorrhage: Secondary Analyses of the ANNEXA-I Randomized Clinical Trial
BACKGROUND: Andexanet improves hemostatic efficacy in FXa (factor Xa) inhibitor–associated intracranial hemorrhage but carries a risk of thrombotic events. These secondary analyses of the ANNEXA-I trial (A Randomized Clinical Trial of Andexanet Alfa in Acute Intracranial Hemorrhage in Patients Receiving an Oral Factor Xa Inhibitor) examined determinants of hematoma expansion (HE) and the corresponding response to andexanet. METHODS: ANNEXA-I enrolled patients aged ≥18 years with acute FXa inhibitor–associated intracranial hemorrhage within 6 hours of onset between June 6, 2019, and May 27, 2023, at 131 sites in 23 countries. Participants were randomized (1:1) to andexanet or usual care. Among 530 participants, 459 (87%) had a qualifying intracerebral hemorrhage and adequate brain imaging for these analyses. The primary outcome was HE (≥12.5-mL or ≥35% increase in baseline volume) at 12 hours. We report differences in the proportion of HE between treatment groups stratified by variables significantly associated with HE in regression models. RESULTS: HE occurred in 149 of 459 participants (32.5%). Symptom onset-to-treatment time (adjusted odds ratio per hour, 0.73 [95% CI, 0.63–0.85]), baseline hematoma volume (adjusted odds ratio per 10 mL, 1.11 [95% CI, 1.01–1.23]), and diastolic blood pressure (adjusted odds ratio per 10 mm Hg, 1.15 [95% CI, 1.02–1.29]) were associated with HE but not thrombotic events. In a separate multivariable model replacing volume and onset-to-treatment time with prescan hematoma growth rate, growth rate was also associated with HE (adjusted odds ratio per mL/h, 1.02 [95% CI, 1.01–1.04]). Patients in the highest risk quartiles (baseline volume >22.4 mL, growth rate >11.4 mL/h, diastolic blood pressure >95.0 mm Hg, and onset-to-treatment time ≤3.3 hours) had ≈50% to 60% absolute risk of HE with usual care. Numerically greater absolute risk reductions with andexanet (≈25%; number needed to treat: 4) were observed in the highest quartiles of baseline volume and growth rate. CONCLUSIONS: Shorter onset-to-treatment time, larger baseline hematoma volume, higher diastolic blood pressure, and higher prescan hematoma growth rate predict HE but not thrombotic events in FXa inhibitor–associated intracerebral hemorrhage. Andexanet benefit is observed across these ranges and may be amplified through patient selection using these metrics. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03661528.
- 17 June 2026
- Published by Elsevier in The Lancet Neurology
- Vol. 25 (7) , 623
Stroke care and prevention in Europe
- 17 June 2026
- Published by Elsevier in The Lancet Neurology
- Vol. 25 (7) , 623
Stroke care and prevention in Europe
- Open Access
- 6 May 2026
- Published by Oxford University Press (OUP) in European Stroke Journal
- Vol. 11 (5)
Cross-national differences in stroke management in the Baltic states: analysis within the Stroke Action Plan for Europe framework
Introduction: Although epidemiological studies often group the Baltic states together, they differ significantly in national stroke care legislation and infrastructure. Our study aimed to explore and compare the current state of stroke care in Lithuania, Latvia and Estonia. Patients and methods: We analysed the Stroke Action Plan for Europe (SAP-E) Stroke Service Tracker data from 2022, including data from the respective National Health Insurance Funds and direct centre-level queries. Geographic Information System-based modelling assessed population access to stroke-ready hospitals within 1 h. Key metrics, including hospitalised stroke incidence, stroke unit admission, recanalisation therapy and in-hospital as well as 30-day mortality, were compared using Z-tests for proportions. Results: The hospitalised stroke incidence per 100,000 inhabitants was similar in Lithuania (353) and Latvia (354), but lower in Estonia (246), despite similar population structures. Lithuania had the highest proportion of its population (94.0%) with access to a stroke-ready hospital within 1 h, followed by Latvia (87.1%) and Estonia (84.7%, P < .001). Estonia had the highest proportion of stroke unit admission rates and the lowest mortality rates—9.6% (in-hospital) and 15.0% (30-day) for ischaemic stroke. Endovascular treatment was most frequent in Lithuania (8.6% of all strokes, P < .001), while Estonia had the highest rate of intravenous thrombolysis (29.0%, P < .001). Conclusions: Despite broadly comparable populations and formal SAP-E alignment, the Baltic states exhibit marked differences in stroke access, treatment and outcomes. High stroke unit admissions and high recanalisation rates in Estonia may be associated with lower ischaemic stroke mortality, underscoring the importance of system design beyond geographic coverage alone.
- 6 May 2026
- Published by Oxford University Press (OUP) in European Stroke Journal
- Vol. 11 (5)
Open AccessCross-national differences in stroke management in the Baltic states: analysis within the Stroke Action Plan for Europe framework
Introduction: Although epidemiological studies often group the Baltic states together, they differ significantly in national stroke care legislation and infrastructure. Our study aimed to explore and compare the current state of stroke care in Lithuania, Latvia and Estonia. Patients and methods: We analysed the Stroke Action Plan for Europe (SAP-E) Stroke Service Tracker data from 2022, including data from the respective National Health Insurance Funds and direct centre-level queries. Geographic Information System-based modelling assessed population access to stroke-ready hospitals within 1 h. Key metrics, including hospitalised stroke incidence, stroke unit admission, recanalisation therapy and in-hospital as well as 30-day mortality, were compared using Z-tests for proportions. Results: The hospitalised stroke incidence per 100,000 inhabitants was similar in Lithuania (353) and Latvia (354), but lower in Estonia (246), despite similar population structures. Lithuania had the highest proportion of its population (94.0%) with access to a stroke-ready hospital within 1 h, followed by Latvia (87.1%) and Estonia (84.7%, P < .001). Estonia had the highest proportion of stroke unit admission rates and the lowest mortality rates—9.6% (in-hospital) and 15.0% (30-day) for ischaemic stroke. Endovascular treatment was most frequent in Lithuania (8.6% of all strokes, P < .001), while Estonia had the highest rate of intravenous thrombolysis (29.0%, P < .001). Conclusions: Despite broadly comparable populations and formal SAP-E alignment, the Baltic states exhibit marked differences in stroke access, treatment and outcomes. High stroke unit admissions and high recanalisation rates in Estonia may be associated with lower ischaemic stroke mortality, underscoring the importance of system design beyond geographic coverage alone.